- Two-stage expansion of the Peachtree City, Georgia site
- Total investment volume of around USD 180 million
- More than 400 new jobs for skilled workers from the
region
- Ramp-up of production beginning end of 2024
DÜSSELDORF, Germany and PEACHTREE CITY, Ga., May 27, 2024
/CNW/ -- Gerresheimer, an innovative systems and
solutions provider and global partner for the pharma, biotech and
cosmetics industries, is significantly expanding its production
capacities for medical systems such as inhalers and autoinjectors
in the United States.
In two expansion stages, Gerresheimer is expanding the
production area at its Peachtree
City site in the state of Georgia,
USA, by around 18,000 m² (194,000 sqft). The company is
investing a total of around 166 million
euros (USD 180 million) in the
construction and equipping of the two new buildings. Gerresheimer
will create more than 400 new jobs in Peachtree City as part of the expansion. The
company currently employs around 270 people at the site. With the
expansion in Peachtree, Gerresheimer is also underscoring its
leading market position as a system and solution provider for drug
delivery systems in the North American market.
"North America is an important
growth market for us. The expansion of the site in Peachtree City is of great importance for our
medical device business in the USA," says Dietmar
Siemssen, CEO of Gerresheimer AG. "The expansion of this
site is therefore currently one of the key projects in our global
capacity expansions based on long-term customer contracts."
Construction work of the first expansion stage almost
completed
In the first stage of expansion, a new building section covering
around 7,700 m² (83,000 sqft) was built directly next to the
existing plant. Around 5,000 m² (53,800 sqft) are intended for ISO
14644-1 cleanroom class 9 production areas. After completion of the
construction work, the installation of the specialized production
technology will begin in the second half of 2024. At the end of
2024, ramp-up of production will start in the new section of the
building. Also part of the new building is a new, automated
high-bay warehouse. After completion of the first stage of
expansion, the Peachtree City site
will have a total of approximately 12,000 m² (130,000 sqft) of
cleanroom class 8 and 9 production space.
Second expansion stage started – new factory hall with growth
option
As part of the second stage of expansion of Gerresheimer's
manufacturing capabilities in Peachtree
City, a completely new 10,200 m² (110,000 sqft) plant is
being built near Atlanta Regional Airport, approximately 2.6 km
(1.6 mi) from the first production site, which will have an
additional 7,200 m² (77,500 sqft) of cleanroom class 9 production
space and also an automated high-bay warehouse. After the
preparatory work for the access road and supply infrastructure, the
construction of the new factory building will soon begin here. In
the course of 2025, the installation of the production and assembly
lines will follow, and production is also scheduled to start here
towards the end of 2025. The factory site on which the new building
is being built also offers enough space for future
expansions.
Becoming one of the largest employers in the region with over
400 new jobs
With the capacity expansions, Gerresheimer is creating more than
400 new jobs for skilled workers in Peachtree City. Once the expansion is
complete, Gerresheimer will be one of the largest employers in the
city, which is located about 40 km (25 miles) southwest of
Atlanta, the capital of the state
of Georgia, with around 700
employees.
At the Peachtree site, Gerresheimer produces medical devices
such as inhalers, components for infusion sets, microinjectors,
test cards for microbiological tests and autoinjectors, which can
be used in diabetes and obesity therapy, among other things.
- Picture is available at AP -
About Gerresheimer
As an innovative system and solution provider, Gerresheimer is the
global partner for the pharmaceutical, biotech and cosmetics
industries. The company offers a comprehensive portfolio of
containment solutions for medicines, drug delivery systems and
medical devices, as well as solutions for the healthcare industry.
The range of services includes digital solutions for therapy
support, drug pumps, syringes, pens, autoinjectors and inhalers as
well as injection vials, ampoules, tablet containers, infusion,
dropper and syrup bottles. Gerresheimer ensures that medications
reach patients safely and can be administered reliably.
With 35 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and
produces locally for the regional markets. With around 12,000
employees, the company generated sales of around 2 billion euros in 2023. Gerresheimer AG is
listed in the MDAX of the Frankfurt Stock Exchange (ISIN:
DE000A0LD6E6).
www.gerresheimer.com
Contact Gerresheimer AG
Jutta Lorberg
Head of Corporate Communication
T +49 211 6181 264
jutta.lorberg@gerresheimer.com
Marion Stolzenwald
Senior Manager Corporate Communication
T +49 1722424185
marion.stolzenwald@gerresheimer.com
View original
content:https://www.prnewswire.com/news-releases/gerresheimer-expands-capacities-for-medical-systems-in-the-usa-302155972.html
SOURCE Gerresheimer AG